Перегляд вихідного коду сторінки Rumors, Lies Coupled With KU-55933

4%]) had 1 dosage adjustment during the study; 14.5% (n = 86) had 2 dose adjustments and 9.9% (n = 59) >2 dose adjustments (which included any dose changes made after administration of the third dose). The most common reason for maintenance dose adjustment was insufficient efficacy (n = 198 [33.4%]). Most dose adjustments were dose reductions (57.8%) rather than dose increases (42.2%). In [http://www.selleckchem.com/products/KU-55933.html KU-55933] total, 61.5% of patients who switched for lack of efficacy showed an improvement of ��20% in mean PANSS total score at LOCF end point (Table III). Efficacy was maintained (ie, change in PANSS total score at end point vs baseline was not inferior as measured by using Schuirmann��s test, P [http://en.wikipedia.org/wiki/PSCD4 CYTH4] to LOCF end point], respectively). There was a statistically significant (P [http://www.selleckchem.com/products/MK-1775.html find more] The CGI-S scale score for all patients improved significantly (mean [SD] decrease, �C0.6 [1.0]; P